Physician profile
Michael Gilmore
NPI 1801858451
$862.54
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $195 · 2021: $157.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $171.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $134.44 | 2019-2021 | |
| Glaxosmithkline, LLC. | $115.61 | 2019 | |
| Alkermes, INC. | $65.53 | 2019 | |
| Pfizer INC. | $53.83 | 2019 | |
| Abbvie INC. | $50.38 | 2021 | |
| Neurocrine Biosciences, INC. | $42.47 | 2019-2020 | |
| Grifols USA, LLC | $36.70 | 2019 | |
| Amgen INC. | $26.16 | 2020-2021 | |
| Gilead Sciences, INC. | $20.93 | 2020 | |
| Lilly USA, LLC | $19.36 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.15 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.74 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.26 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $17.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apria Healthcare LLC | $15.33 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.42 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.59 | 2021 | |
| Allergan, INC. | $12.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.